Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05093517 · ClinicalTrials.gov registry record · Early Phase 1

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

A Early Phase 1 study of Type 2 Diabetes and Insulin Sensitivity, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Early Phase 1
Development phase
4
Enrollment target
1
Study location

NCT05093517: Completed Early Phase 1 study of Type 2 Diabetes and Insulin Sensitivity, sponsored by The University of Texas Health Science Center at San Antonio.

NCT05093517 is a Early Phase 1 study of Type 2 Diabetes and Insulin Sensitivity that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 4 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05093517, a Early Phase 1 study of Type 2 Diabetes and Insulin Sensitivity, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Early Phase 1
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

With REMD's glucagon receptor antagonist, the study team propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in Type 2 Diabetes Mellitus (T2D) patients on: (i) glucose tolerance; (ii) insulin sensitivity in liver, muscle, and adipocytes; (iii) beta cell function; (iv) adipocyte inflammation.

Primary Outcome

Change in HbA1c measured at baseline and after intervention administration

Conditions Studied

Type 2 Diabetes Insulin Sensitivity Glucose Tolerance Impaired

Interventions

  • DRUG REMD-477
  • DRUG Placebo Subcutaneous injection

Study Locations (1)

Texas

  • Texas Diabetes Institute - San Antonio

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2021-11-10
Est. Completion 2022-03-16
Phase Early Phase 1
The University of Texas Health Science Center at San Antonio

378 total trials

What the finished NCT05093517 record still lists

NCT05093517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower).

The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which REMD-477 is the first listed.

NCT05093517 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05093517 about?

NCT05093517 is a clinical study titled "Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM". With REMD's glucagon receptor antagonist, the study team propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in Type 2 Diabetes Mellitus (T2D) patients on: (i) glucose tolerance; (ii) insulin sensitivity in liver, muscle, and adipocytes; (iii) bet...

What is the current status of trial NCT05093517?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2021-11-10. Estimated completion is 2022-03-16.

What conditions does trial NCT05093517 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Insulin Sensitivity, Glucose Tolerance Impaired.

What interventions are being tested in trial NCT05093517?

The interventions under investigation include: REMD-477 (DRUG), Placebo Subcutaneous injection (DRUG).

Who is sponsoring clinical trial NCT05093517?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05093517 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05093517's enrollment target sits among peer trials

4 328th of 327 the lowest of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05093517, the US trial registry maintained by the National Library of Medicine. NCT05093517 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.